A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease

Ellen M. Hartenbach, Andrew K. Saltzman, Jonathan R. Carter, Leo B. Twiggs

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.

Original languageEnglish
Pages (from-to)105-108
Number of pages4
JournalGynecologic Oncology
Volume56
Issue number1
DOIs
StatePublished - Feb 7 1995
Externally publishedYes

Fingerprint

Gestational Trophoblastic Disease
Dactinomycin
Vincristine
Granulocyte Colony-Stimulating Factor
Etoposide
Methotrexate
Cyclophosphamide
Drug Therapy
Therapeutics
Subcutaneous Injections
Neutropenia
Appointments and Schedules

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. / Hartenbach, Ellen M.; Saltzman, Andrew K.; Carter, Jonathan R.; Twiggs, Leo B.

In: Gynecologic Oncology, Vol. 56, No. 1, 07.02.1995, p. 105-108.

Research output: Contribution to journalArticle

Hartenbach, Ellen M. ; Saltzman, Andrew K. ; Carter, Jonathan R. ; Twiggs, Leo B. / A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. In: Gynecologic Oncology. 1995 ; Vol. 56, No. 1. pp. 105-108.
@article{0375c037312043d0a56eed8affe2523b,
title = "A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease",
abstract = "EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.",
author = "Hartenbach, {Ellen M.} and Saltzman, {Andrew K.} and Carter, {Jonathan R.} and Twiggs, {Leo B.}",
year = "1995",
month = "2",
day = "7",
doi = "10.1006/gyno.1995.1019",
language = "English",
volume = "56",
pages = "105--108",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease

AU - Hartenbach, Ellen M.

AU - Saltzman, Andrew K.

AU - Carter, Jonathan R.

AU - Twiggs, Leo B.

PY - 1995/2/7

Y1 - 1995/2/7

N2 - EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.

AB - EMA/CO (etoposide-methotrexate-actinomycin D and Cytoxan-Oncovin) is an effective and well-tolerated chemotherapy regimen for the treatment of high- risk gestational trophoblastic disease. However, it is associated with significant neutropenia often requiring dose reductions and treatment delays. We describe, the use of granulocyte colony-stimulating factor (G-CSF) in three patients in order to maintain the treatment schedule. A subcutaneous injection of 5 μg/kg/day was administered on Days 3-6 and 9-14 of each chemotherapy cycle. No patients had any adverse effects and all received full chemotherapy doses without any treatment delay. The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease.

UR - http://www.scopus.com/inward/record.url?scp=0028917983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028917983&partnerID=8YFLogxK

U2 - 10.1006/gyno.1995.1019

DO - 10.1006/gyno.1995.1019

M3 - Article

C2 - 7529741

AN - SCOPUS:0028917983

VL - 56

SP - 105

EP - 108

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -